MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

ClinicalTrials.gov ID: NCT01437657

Public ClinicalTrials.gov record NCT01437657. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients With Major Depressive Disorder With Inadequate Response to Ongoing Antidepressant Treatment

Study identification

NCT ID: NCT01437657
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 319 participants

Conditions and interventions

Conditions

Major Depressive Disorder

Interventions

Placebo Drug
RO4917523 0.5 mg Drug
RO4917523 1.5 mg Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2011
Primary completion: Aug 31, 2013
Completion: Aug 31, 2013
Last update posted: Nov 1, 2016

2011 – 2013

United States locations

U.S. sites: 28
U.S. states: 13
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72223	—
Not listed	Costa Mesa	California	92626	—
Not listed	Garden Grove	California	92845	—
Not listed	Oceanside	California	92056	—
Not listed	Orange	California	92868	—
Not listed	Riverside	California	92506	—
Not listed	San Diego	California	92102	—
Not listed	San Diego	California	92103	—
Not listed	San Diego	California	92121	—
Not listed	Santa Ana	California	92705	—
Not listed	Wildomar	California	92595	—
Not listed	Atlanta	Georgia	30328	—
Not listed	Libertyville	Illinois	60048	—
Not listed	Naperville	Illinois	60563	—
Not listed	Oak Brook	Illinois	60523	—
Not listed	Shreveport	Louisiana	71115	—
Not listed	Baltimore	Maryland	21285	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	Marlton	New Jersey	08053	—
Not listed	Brooklyn	New York	11201	—
Not listed	Cedarhurst	New York	11516	—
Not listed	Oklahoma City	Oklahoma	73112	—
Not listed	Norristown	Pennsylvania	19403	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	Philadelphia	Pennsylvania	19139	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Memphis	Tennessee	38119	—
Not listed	Kirkland	Washington	98033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01437657, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Jul 24, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01437657 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →